The fate of coronary dissections left after sirolimus‐coated balloon angioplasty: A prespecified subanalysis of the EASTBOURNE study
This subgroup analysis of the EASTBOURNE study, the largest prospective study on drug-coated balloons (DCB) to date, focused on the clinical outcomes of dissections left untreated after sirolimus DCB angioplasty. The analysis included all patients with coronary artery disease who were treated with the new-generation sirolimus DCB. The results showed that dissections left untreated after angioplasty did not result in higher rates of adverse events at the 12-month follow-up. This suggests that type A-B dissections left untreated after sirolimus DCB are safe in terms of long-term clinical outcomes.
Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients
Drug-coated balloons (DCB) have been hailed as a revolutionary advancement in interventional cardiology, with the potential to replace drug-eluting stents. One type of DCB, sirolimus-coated balloons (SCB), is currently being studied for various applications in treating coronary artery disease. The EASTBOURNE study, which enrolled over 2,000 patients at 38 centers, shows the promising results of using a novel SCB for the treatment of this condition, including small vessels and in-stent restenosis. This study highlights the potential for DCBs to become a safe and effective alternative to traditional stent procedures.
Sirolimus-coated balloon in acute and chronic coronary syndromes: subanalysis of the EASTBOURNE registry
The PEACE study found that the use of a sirolimus-coated balloon (SCB) from Concept Medical, India, showed positive results in both acute coronary syndromes (ACS) and chronic coronary syndromes (CCS). This was a post-hoc analysis of the EASTBOURNE Registry, which included 2083 patients, with 960 (46.5%) being treated for ACS and 1115 (53.0%) for CCS. The SCB demonstrated good performance in terms of both acute and 1-year outcomes, regardless of the patient’s clinical presentation. These findings suggest that the use of a sirolimus-coated balloon could be a promising treatment option for both ACS and CCS patients.
Functional (Re)Development of SYNTAX Score II 2020: Predictive Performance and Risk Assessment
The current research delves into the potential of the Syntax Score Il 2020, which takes into account flow-limiting lesions, in predicting the effectiveness of treatment for patients with left main or multivessel disease. The study, which examined 1274 patients from the HALE-BOPP cohort, incorporated the result of fractional flow reserve (FFR) evaluation into the Syntax Score Il 2020. The findings suggest that the combination of clinical, anatomical, and functional data can improve risk prediction and guide treatment decisions.
Cardiotalk Journal Map: Interview with Dr. Bernardo Cortese
In this interview, Prof. Cortese highlighted the significance of drug-coated balloon (DCB) technology in treating various types of lesions and its potential to revolutionize angioplasty. He mentioned studies such as PICCOLETO Il and EASTBOURNE, which have shed light on the effectiveness of this approach. This interview provided valuable insights into the advancements in medical technology and the potential benefits they could bring to patients.
Long-term benefits of drug-coated balloons for coronary artery revascularization
Several studies have also shown that DES is associated with a higher risk of target vessel revascularization compared to CABG after long-term follow-up. However, drug-coated balloons (DCB) have been shown to provide significant clinical benefits in the treatment of in-stent restenosis, diffuse coronary artery disease, and small coronary artery lesions. Therefore, this review aimed to highlight the limitations of DES and showcase the potential advantages of using PCI with DCB for long-term outcomes, potentially demonstrating its non-inferiority to CABG.
Drug-coated balloons on the “big stage”: is this technology ready for an all-comer population with de novo lesions?
Nonostante i vantaggi dell’utilizzo di palloni a rilascio di farmaco (DCB) per il trattamento della malattia coronarica, ci sono ancora preoccupazioni sul fatto di lasciare dietro di sé una dissezione coronarica residua, in particolare nelle lesioni de novo. Tuttavia, è stato dimostrato che una dissezione non limitante il flusso dopo il trattamento con DCB tende a guarire durante i primi mesi, sia con la tecnologia paclitaxel che con quella di sirolimus, senza portare alla chiusura acuta o subacuta dei vasi. Inoltre, ci sono prove che una corretta preparazione della lesione sia fondamentale per il successo del DCB, con un palloncino completamente espanso delle dimensioni corrette e una gestione accurata delle calcificazioni e della stenosi residua che sono necessari per una somministrazione efficace del farmaco. Pertanto, sebbene i DCB possano essere una valida alternativa al tradizionale intervento coronarico percutaneo, dovrebbero essere utilizzati solo come passaggio finale e in combinazione con un’adeguata preparazione della lesione.